Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...
TME Pharma Announces Acceptance of the NCI’S Abstract on NOX-A12 in Glioblastoma for Presentation at the SNO 2024 Annual Meeting
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...
TME Pharma Announces Oral Presentation at ESMO Congress 2024 With Updated Results From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...